Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market worth $ 635.9 million by 2028 - Exclusive Report by InsightAce Analytic

The newly published report titled "Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market- By Trends, Industry Competition Analysis, Covid-19 Analysis, Revenue (US$ Millions) and Forecast Till 2030." features in-depth analysis and an extensive study on the LBP and Microbiome manufacturing industry, exploring its significant factors.

The global market for live biotherapeutic products (LBP) and microbiome contract manufacturing was estimated to be worth US$ 41.8 million in 2021 and is projected to grow to US$ 635.9 million in 2028, with a promising compound annual growth rate (CAGR) of 47.54% from 2021 to 2030, according to the most recent market research report from InsightAce Analytic.

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1152

Recent decades have seen advancements in the microbiome study, which has become a promising field for novel therapeutic interventions. In addition to human health, microbiome research provides a basis for various uses. Almost every facet of human health depends on the microbiome, which comprises the microorganisms that live in and on the human body. There is growing evidence that a novel class of live biotherapeutics based on altered microbes may be able to cure particular disease pathways, and the significance of microorganisms in human health and various diseases is becoming more widely acknowledged. Many biotech and pharmaceutical companies worldwide are developing a novel therapeutic approach called Live Biotherapeutic Products (LBP), sometimes known as bugs-as-drug. A novel class of medications based on live bacteria, known as Live Biotherapeutic Products (LBPs), has shown promise in treating challenging diseases. Between 2010 and 2019, the number of new pharmaceuticals allowed for sale rose by 60% compared to the previous year, peaking at 59 new drugs approved in 2018.

The market is predicted to rise throughout the forecast period due to a rising pipeline of microbiome-targeting medicines and increased research and development activities. These therapies are expected to cure a wide range of severe disorders. The market is expanding due to ongoing innovation and technological developments in creating new drugs and clinical trial operations to treat illnesses. There should be substantial growth potential during the foreseeable period due to increased government financing and R&D expenditure for medication development. The global market for microbiome contract manufacturing and live biotherapeutic products (LBP) is anticipated to expand due to the COVID-19 pandemic. The COVID-19 pandemic has significantly impacted clinical trial execution globally and created several interruptions in the healthcare sector. Other critical Challenges affecting the industry, however, are the absence of infrastructure, the particular requirements for creating modified live bacterial treatments, and the uncertainty surrounding regulatory assessment and product approval.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

The prominent players in the Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing industry include:
Quay Pharmaceuticals, Cobra Biologics Limited, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio, BacThera, Luina Bio Pty Ltd, 4D pharma plc, Paras Biopharmaceuticals Finland Oy, Capsugel, Deerland Probiotics & Enzymes, Paragon Bioservices, UAS Labs, Biose, Cobra Biologics, Cerbios, Inpac Probiotics, BJP Laboratories, S-Biomedic, Meteoric Biopharmaceuticals, BiomX, Universal Stabilization Technologies, Assembly Biosciences, Wacker Biotech, Chung Mei Pharmaceutical and Other Prominent Players.
Key Industry Developments from Leading Players:
• In Nov 2021, Bacthera and Seres Therapeutics announced a collaboration to manufacture SER-109, Seres' lead product candidate for recurrent Clostridioides difficile infection (CDI). Under the terms of the agreement, Bacteria is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of s located on Lonza's Ibex campus in Visp, Switzerland. The agreement between Bacteria and Seres Therapeutics aims to expand upon Seres' initial commercial manufacturing supply chain
• In May 2021, Bacthera's drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera's drug substance facility in Hørsholm, Denmark, both facilities had been granted manufacturing licenses by the respective national health authorities. The permit will allow the Company to fulfill the scope of bringing innovative Live Biotherapeutic Products (LBP) to patients with unmet medical needs
• In Nov 2019, Arranta Bio has received an US$82 million funding round and a strategic partnership with Thermo Fisher Scientific.Through this partnersship with Thermo Fisher, Arranta has access to the company's a wide range of product portfolio and services and provided materials to Thermo Fisher for use in gene therapy production
• In Oct 2019, 4D pharma plc announced research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc. to discover and develop Live Biotherapeutics ("s") for vaccines. Through this agreement, 4D's proprietary MicroRx platform will be paired with MSD's expertise in developing and commercializing novel vaccines to discover and develop s as vaccines in up to three undisclosed indications
• In April 2019, Chr. Hansen Holding A/S and Lonza AG equally shared approximately €90m ($101.5m) to establish a CDMO (contract development and manufacturing organization) for biotherapeutic products. The investment was in two phases, bagan with an update to Lonza's existing facilities in Hørsholm, Denmark, for cGMP production of drug substances (anaerobic bacteria). It also equiped new facilities in Basel, Switzerland, for drug product development and manufacturing.

Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Regional Analysis:
North America dominated the global market, contributing for the majority share of the market in 2021. On account of rising R&D spending and the high adoption of new technology, the Region is likely to lead the global market during the forecast period. Intense research and a commercial base for live biotherapeutic and microbiome products and the presence of biopharmaceutical Contract manufacturers are factors contributing to the regional market's growth. Asia Pacific is also projected to expand at the significant growth over the forecast period. Due to key market players' increasing research and development activities, Europe is expected to witness significant growth during the forecast period.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/1152

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Segments
The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2030 based on Product Manufactured
• APIs
• FDFs

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2030 based on Type of Formulation
• Solid Formulations
• Oral Liquids
• Injectables
• Others

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2030 based on Scale of Operation
• Preclinical Scale Operations
• Clinical Scale Operations
• Commercial Scale Operations

The Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2030 based on Company Size
• Small-sized Companies
• Mid-sized Companies
• Large Companies

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• Europe
• North America
• Latin America
• Asia Pacific
• Middle East & Africa
North America Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada
Europe Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market Estimates Revenue (US$ Million) by Country, 2022 to 2030
• South Africa
• GCC Countries
• Rest of the Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ www.insightaceanalytic.com/buy-report/2444

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.